greeksoup/ stock research

SBC Medical Group Holdings Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 13 August 2026: press release. Guidance figures: 1 new. The quarter’s numbers.

Key takeaways

  • Revenue rose 13% in the quarter: Total revenue was $49.2 million against $43.4 million a year earlier. Management attributed the period’s growth to the points business and service fees. Source
  • Net income rose on points and fees: Net income attributable to SBC Medical was $10.7 million, against $2.5 million a year earlier. Management cited points business growth and higher service fees. Source
  • Management describes a reacceleration: Management said net income growth outpaced revenue growth, which it described as a reacceleration in growth. Source
  • Locations up 34 to 287: Locations across the support and partnership network, including franchised SBC-branded clinics, reached 287 at June 30, 2026. Source
  • Patient visits up 10%: Last-twelve-month patient visits reached 6.9 million, up 10%, counted across SBC-branded and partner clinics. Source
  • Adjusted EBITDA up 32%: Adjusted EBITDA was $20.1 million with a 41% margin, up six points. First-half adjusted EBITDA was $38.5 million, down 4%, at a 42% margin. Source
  • Annual fee gain estimated at $15 million: If realized for a full year, the initiatives are expected to raise service fees by about $15 million annually, converted at ¥158.1/US$. Source
  • Cash balance reached $184 million: Cash and cash equivalents were $184.3 million at June 30, 2026, up from $163.8 million at December 31, 2025. Source
  • Operating cash flow rose in first half: Net cash provided by operating activities was $31.7 million in the first half, against $6.4 million used in the prior-year period. Source

“We believe our results this quarter clearly demonstrate that SBC Medical’s growth story has entered a new phase.”

Yoshiyuki Aikawa, Chairman and CEO

Guidance

AreaPeriodFigureAgainst last quarter
Service fees SourceAnnual, if the full-year impact is realizedapproximately $15 million annuallyNew

What changed from last quarter

  • New guidance: Management gave a first estimate of about $15 million in added annual service fees, if realized for a full year. Source
  • New: The points business expanded following a change in the company’s operating policy, which management cited as a driver of earnings growth. Source
  • New: Fee revisions for call center services at five affiliated corporations, and separate revisions for Rize Clinic and Gorilla Clinic, were referred to as being pursued. Source
  • New: Management said it is preparing to enter the Longevity market; the prior release had said it would pursue opportunities in that market. Source

Results and growth drivers

  • Revenue rose 13% in the quarter: Total revenue was $49.2 million against $43.4 million a year earlier. Management attributed the period’s growth to the points business and service fees. Source
  • Net income rose on points and fees: Net income attributable to SBC Medical was $10.7 million, against $2.5 million a year earlier. Management cited points business growth and higher service fees. Source
  • Management describes a reacceleration: Management said net income growth outpaced revenue growth, which it described as a reacceleration in growth. Source
  • Basic EPS rose to ten cents: Basic and diluted EPS was $0.10 for the quarter, against $0.02 a year earlier. Source
  • First-half net income fell: First-half revenue was $92.2 million, up 2%, while net income attributable to SBC Medical fell 8% to $22.0 million. Source

Network and patient volumes

  • Locations up 34 to 287: Locations across the support and partnership network, including franchised SBC-branded clinics, reached 287 at June 30, 2026. Source
  • Patient visits up 10%: Last-twelve-month patient visits reached 6.9 million, up 10%, counted across SBC-branded and partner clinics. Source
  • Spend per visit rose 9%: Average spend per visit was $287, up 9% year-over-year. Source

“I am growing increasingly confident that this reacceleration is not a temporary phenomenon but reflects the strengthening of our underlying growth fundamentals.”

Yoshiyuki Aikawa, Chairman and CEO

Revenue mix and related parties

  • Related-party revenue grew 12%: Revenue from related parties was $43.7 million, against $38.9 million a year earlier. Revenue from other parties was $5.5 million, against $4.4 million. Source
  • Related-party receivables rose: Accounts receivable from related parties were $40.7 million at June 30, 2026, against $27.5 million at December 31, 2025. Source
  • Related-party other receivables appeared: Other receivables from related parties were $1.6 million at June 30, 2026, against nil at December 31, 2025. Source

Costs, margins and earnings

  • Adjusted EBITDA up 32%: Adjusted EBITDA was $20.1 million with a 41% margin, up six points. First-half adjusted EBITDA was $38.5 million, down 4%, at a 42% margin. Source
  • Net income margin reached 22%: Net income margin was 22%, up 16 points, and annualized return on equity was 16%, against 4% a year earlier. Source
  • Gross profit rose on lower cost: Cost of revenues was $13.2 million, against $13.3 million, and gross profit rose to $36.0 million from $30.0 million. Source
  • Operating expenses rose: Selling, general and administrative expenses were $17.0 million, against $15.5 million, and income from operations was $19.0 million. Source
  • Income tax expense fell: Income tax expense was $7.8 million, against $11.1 million, and foreign currency exchange moved to a $1.0 million gain from a loss. Source
  • Equity-method loss recorded: Equity in losses of equity method investees, net of tax, was $0.6 million in the quarter, with no comparable amount in the prior-year quarter. Source

“Having completed the structural reforms we undertook in 2025, we are now running multiple growth engines simultaneously.”

Yoshiyuki Aikawa, Chairman and CEO

AI services and service fees

  • AI tools cited behind service fees: Management cited AI-powered call centers, AI-driven marketing and AI-assisted site selection as part of enhanced support for affiliated clinics. Source
  • Fee revisions at five affiliates: Management referred to call center fee revisions at five affiliated corporations, plus separate revisions for Rize Clinic and Gorilla Clinic. Source
  • Annual fee gain estimated at $15 million: If realized for a full year, the initiatives are expected to raise service fees by about $15 million annually, converted at ¥158.1/US$. Source
  • Fee changes pursued on a win-win basis: Management said the fee changes are pursued in a disciplined manner, premised on a win-win relationship with affiliated medical corporations. Source
  • Platform growth tied to visits: Management described a cycle in which platform appeal lifts patient visits and treatment volumes, leading to expanded service fees. Source

Strategy and growth engines

  • Non-aesthetic as second growth engine: Management said it will deepen its multi-brand strategy in domestic aesthetic dermatology and expand non-aesthetic business, which it calls a second growth engine. Source
  • OrangeTwist and Thailand expansion: International growth is planned through the OrangeTwist collaboration in the United States and ASEAN expansion anchored in Thailand. Source
  • Network expansion positioned to accelerate: The release headline states that the AI-enabled service enhancements position the business for accelerated network expansion. Source

Cash, borrowings and shareholder returns

  • Cash balance reached $184 million: Cash and cash equivalents were $184.3 million at June 30, 2026, up from $163.8 million at December 31, 2025. Source
  • Operating cash flow rose in first half: Net cash provided by operating activities was $31.7 million in the first half, against $6.4 million used in the prior-year period. Source
  • Bank borrowings repaid in first half: Repayments of bank and other borrowings were $3.7 million in the first half; total bank and other borrowings were $37.8 million at June 30. Source
  • No share repurchases in first half: No common stock was repurchased in the first half of 2026, against $2.4 million in the first half of 2025. Shares outstanding stayed at 102,576,943. Source

Prior quarter and 2025 reform

  • First-quarter revenue fell 9%: First-quarter revenue was $43 million, down 9%, which management attributed mainly to a structural reform implemented in April 2025 that revised the franchise fee structure.
  • First-quarter net income fell 47%: First-quarter net income attributable to SBC Medical was $11 million, down 47%, with a net income margin of 26%, down 19 points.
  • Franchise locations up 33 a year earlier: The first-quarter release reported 284 franchise locations at March 31, 2026, an increase of 33 from March 31, 2025.

Coming up, as management said on 13 August 2026

  • Investment toward next growth phase: Management said it will continue disciplined investment toward the next growth phase using its cash balance. Source

Figures management reported

FigureReported
Patient visits (last twelve months) Source6.9 million, up 10% year-over-year
Average spend per visit Source$287, up 9% year-over-year
Locations in support and partnership network Source287, up 34 year-over-year

Earlier plans management reported on

  • Met: Management said the structural reforms undertaken in 2025 have been completed. Source
  • Not stated: The prior release said the multi-brand strategy would continue; the current release says it will be deepened domestically.
  • Not stated: The prior release said the company would pursue Longevity market opportunities; the current release says it is preparing to enter that market.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.